CA-OMNICELL
4.1.2021 14:02:10 CET | Business Wire | Press release
Omnicell, Inc. (Nasdaq: OMCL), a leading provider of medication management and supply chain solutions for health systems, today announced its intent to enter a new partnership with Guy’s and St Thomas’ NHS Foundation Trust, London to develop technology-enabled inventory optimization and intelligence services.
As part of a £10.5 million capital investment, the South East London Integrated Care System (ICS) will expand the deployment of Omnicell automation systems across six acute hospital sites. This also includes the opportunity for Omnicell and the Trust to launch a European-based technology-enabled intelligence center with the aim to deliver advanced analytics to manage supplies and medications. Combined with the expansion of Omnicell automated dispensing systems across the South East London hospitals, it is expected that this technology-enabled intelligence center will provide a high level of visibility and actionable insights for the South East London Integrated Care System to improve efficiency and patient safety.
The Integrated Care System includes two of the UK’s biggest hospital trusts, Guy’s and St Thomas’ NHS Foundation Trust and Kings College Hospital NHS Foundation Trust, as well as Lewisham and Greenwich NHS Trust. These Trusts are already using a mix of Omnicell’s XT supply and medication dispensing systems to manage clinical inventory and medications. The ICS successfully secured capital funding from the Department of Health Wave IV Estate Transformation Fund to undertake a regional supply chain transformation program.
By choosing Omnicell as its sole Inventory Management Solution, the Integrated Care System will be able to deliver consistency of practice and openly share data through a single instance based in the cloud. These systems, coupled with the expected technology-enabled intelligence centre based at Guy’s and St Thomas’, aim to provide total visibility of all medication and clinical inventory across the region. The solution will leverage the latest AI tools to provide real-time analytic support and system optimization. This will help reduce the risk of dispensing errors and help deliver the right medication, in the right place, at the right time.
Omnicell’s cloud-based intelligence, automation, and technology-enabled services are helping health systems across the globe to:
- support patient safety
- drive efficiencies
- reduce unnecessary and costly wastage
- allow healthcare professionals to increase their time for face-to-face patient care.
David Lawson, Chief Procurement Officer for Guy’s and St Thomas’, said: “We are delighted to join with Omnicell to bring this cutting-edge solution to the UK. The Trust has successfully deployed Omnicell systems for supplies and medication for over 10 years and the opportunity of this new intelligence offering alongside the expansion of Omnicell systems across South East London represents the next chapter in a successful long term partnership with Omnicell. Through this collaboration, South East London hopes to develop new AI tools to reduce variation between hospital sites and optimize system performance to allow for improved patient outcomes and operational efficiency at a regional level.”
Sara Dalmasso, vice president and general manager, International, at Omnicell said: “Expanding technology-enabled services and intelligence solutions reflects our ambition to deploy advanced analytic and optimization tools to support health systems across Europe. This new partnership with Guy’s and St Thomas’ also demonstrates that Omnicell is quickly becoming the go-to provider for regional medication and supply management solutions across the UK. We are hugely excited to be offered another opportunity to work with a likeminded partner who wants to reshape how automated inventory and medical supply management systems are viewed in the NHS and the wider European market. We share a goal of improving healthcare and patient safety, and I’m looking forward to working with Guy’s and St Thomas’ and South East London to support our joint vision.”
About Guy’s and St Thomas’ and South East London Integrated Care System
Guy’s and St Thomas’ provides 2.6 million patient contacts in acute and specialist hospital services and community services every year. As one of the biggest NHS trusts in the UK, with an annual turnover of almost £1.7 billion, we employ around 18,000 staff. To learn more, visit: www.guysandstthomas.nhs.uk
South East London Integrated Care System brings together local health and care organisations and local councils to re-design care and improve population health through shared leadership and collective action. It covers six London boroughs, Bexley, Bromley, Greenwich, Lambeth, Lewisham and Southwark, with 1.9 million patients. Priorities include reducing costs through provider collaboration and changing the way they work together to deliver transformation. To learn more, visit: https://www.ourhealthiersel.nhs.uk/
About Omnicell
Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs. Through the vision of the autonomous pharmacy, a combination of automation, intelligence, and technology-enabled services, powered by a cloud data platform, Omnicell supports more efficient ways to manage medications across all care settings. Over 7,000 facilities worldwide use Omnicell automation and analytics solutions to help increase operational efficiency, reduce medication errors, deliver actionable intelligence, and improve patient safety. More than 50,000 institutional and retail pharmacies across North America and the United Kingdom leverage Omnicell's innovative medication adherence and population health solutions to improve patient engagement and adherence to prescriptions, helping to reduce costly hospital readmissions. To learn more, visit www.omnicell.com .
OMCL-G
View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005125/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom